The effect of once-daily dosage of the two most widely prescribed cardioselective beta-adrenoceptor antagonists used to treat hypertension-namely, atenolol and metoprolol-was studied in nine carefully selected hypertensive outpatients. Each patient received atenolol 50 mg/ day, atenolol 100 mg/day, metoprolol 100 mg/day, and metoprolol 200 mg/day in a sustained-release formulation (as Lopresor SR) according to a randomised sequence. After three weeks' treatment with each drug given once daily comparisons of the treatments 24 hours after dosing showed no important differences between 50 and 100 mg atenolol/day. Metoprolol, as both the standard and the slow-release formulations, had some limitations in controlling systolic blood pressure and heart rate.
Introduction
Once-daily dosage of cardioselective beta-adrenoceptor antagonists in the treatment of hypertension is widely promoted despite uncertainty about the optimal dosage that is effective over 24 hours. For example, atenolol 50 mg once daily has recently been recommended in the United States and Australia, whereas the more costly 100 mg/day is suggested to prescribers in the United Kingdom. Metoprolol 100 mg once daily has been claimed to be effective,1 2 but two manufacturers have developed a slow-release formulation of metoprolol for once-daily use. The aim of this study was to investigate the effects at intervals over 24 hours of different doses of atenolol and metoprolol administered once daily.
Patients and methods
Nine patients (eight men) with established hypertension and normal renal and hepatic function took part in the study. Their mean age was 37 (range 23-49) years and weight 82 (range 65-102) kg.
None of the patients suffered from conditions in which beta-adrenoceptor antagonists were contraindicated. The study was approved by the local area ethical committee, and all patients gave informed written consent to participate in the study.
Each patient received all four treatments in random ordernamely, atenolol 50 mg/day; atenolol 100 mg/day; metoprolol (sustained release; Lopresor SR) 200 mg/day; and metoprolol (Lopresor) 100 mg/day. Any other medication had been withdrawn at least three weeks before the study. Patients attended the ward for training and familiarisation with the techniques and procedures and for untreated values to be recorded. On the last day of each threeweek period of active treatment the patients attended the ward between 8 and 9 am, 24 hours after their last dose. Heart rate and blood pressure were measured. A further dose was then given and the measurements repeated four and 12 hours after this final dose in each treatment period. Heart rates and blood pressures were recorded sitting (in duplicate) after 10 minutes' rest, standing (in duplicate) after two minutes, during exercise after three minutes on a treadmill at 151) (at a speed predetermined for each patient to achieve untreated exercise heart rate of -140 beats/min), and 30 seconds after exercise. The observer was unaware of the treatment being given. A Remler recorder (M2000) coupled direct to a decoder (M3000) was used for simultaneous measurement of both heart rate and blood pressure.3 On the day of each study the patients had a light breakfast, went about their usual daily routine (other than ward visits for recording), and were forbidden alcohol, cigarettes, and caffeine-containing drinks.
Blood samples (10 ml) were taken within two minutes of each postexercise recording and analysed by gas-liquid chromatography with electron capture detection (atenolol4; metoprolol5). Data on heart rate and systolic and diastolic pressures in the different positions were analysed by analyses of variance. Because of interactions separate analyses of variance were then computed for elapsed times of four, 12, and 24 hours. Pairs of means were compared by Scheffe's method, which adjusts significance levels to allow for multiple comparisons, and the results confirmed using Wilcoxon's signed rank test, which requires less stringent assumptions regarding the type of measurements being made.
Results
Heart rates and blood pressure- Table I shows the mean sitting, standing, exercise, and postexercise heart rates and systolic and diastolic blood pressures at four, 12, and 24 hours after dosing for the four treatments. Values for the least significant differences at the 50°, level are included and indicate the smallest difference between any pair of means that would be declared significant at the 5% level.
Each value is appropriate for any of the six pairs of differences that can be selected from the four means. The use of least significant differences rather than standard errors of means allows for direct interpretation of clinically relevant differences between treatments.
Heart rate and systolic blood pressure-Four and 12 hours after dosing the mean values of these two variables were similar in each position for all treatments. At 24 hours after dosing the effects of both doses of atenolol were similar. Comparisons of the four treatments favoured atenolol (table II) .
Diastolic blood pressure-No significant differences were evident between the treatments in diastolic blood pressure in any position at any of the times measured.
Blood concentrations- Table III shows blood concentrations of the drugs four, 12, and 24 hours after dosing for the four treatments.
In each case the concentrations were correlated with the dose administered.
Discussion
This study shows that the present recommendations for dosages of both atenolol and metoprolol in the management of hypertension should be reconsidered. There seems little to justify the routine initial prescription of atenolol 100 mg/day when the lower dose is almost as effective and much cheaper (by £24/patient/year). A previous study by our group showed that 50, 100, and 200 mg atenolol once daily had similar effects, but the study did not include measurements at four and 12 hours after dosing or during exercise, or measurements of blood concentrations.6 Thus for reasons of cost and effectiveness We previously compared atenolol and metoprolol given twice daily (200 mg and 400 mg daily) and found no important differences.7 Our present study shows that 24 hours after dosing comparisons of lower doses of atenolol and metoprolol given once daily, even using a slow-release formulation of metoprolol, do not favour metoprolol. The 100 mg standard formulation of metoprolol has limitations for once-daily dosage, while the higher dose of the slow-release formulation also has limitations compared with both doses of atenolol in controlling heart rates and systolic blood pressure.
Two principal claims are made by proponents of once-daily treatment with beta-adrenoceptor antagonists, and each merits critical consideration. The more important is that control of heart rate and blood pressure 24 hours after dosing is necessary to reduce morbid events and mortality. There is little accumulated evidence to support such claims. Blood pressure is lower during sleep, and the achievement of blood concentrations of drugs necessary to inhibit exercise-induced tachycardia is seldom appropriate in the early hours of the morning if this time coincides with the terminal phase of the dosing interval. Nevertheless, if claims are made for the effectiveness of a formulation of a drug 24 hours after dosing then such claims should withstand scrutiny. As we have shown in this study and previously"8 this is not always the case. The less important claim is that once-daily dosing improves compliance of the patient with drug treatment. We do not consider that this is proved.
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